A call to action: MTHFR polymorphisms should not be a part of inherited thrombophilia testing. Issue 4 (8th June 2022)

• Record Type: Journal Article
• Authors: Deloughery, Thomas G.; Hunt, Beverley J.; Barnes, Geoffrey D.; Connors, Jean M.
• Other Names: Ay Cihan investigator.; Barco Stefano investigator.; Castellucci Lana investigator.; Cesarman‐Maus Gabriela investigator.; Paula Erich Vinicius De investigator.; Dumantepe Mert investigator.; Esposito Maria Cecilia Guillermo investigator.; Fedele Federica investigator.; Lee Lai Heng investigator.; McLintock Claire investigator.; Morishita Eriko investigator.; Samama Charles Marc investigator.; Okoye Helen investigator.; Robertson Todd investigator.
• Is Part Of: Research and practice in thrombosis and haemostasis. Volume 6:Issue 4(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-06-08
• Subjects: guidelines -- homocysteine -- MTHFR -- testing -- thrombophilia; Thrombosis -- Periodicals; Hemostasis -- Periodicals; 616.135005
• DOI: 10.1002/rth2.12739
• Languages: English
• ISSNs: 2475-0379

Abstract

Abstract: Testing for polymorphisms in the methylenetetrahydrofolate reductase (MTHFR) gene is still a standard part of thrombophilia testing in many laboratories. However, it is clear that these polymorphisms are not risk factors for arterial or venous thrombosis and therefore should not be part of thrombophilia testing. Eliminating MTHFR from thrombophilia testing will reduce patient concerns and health care costs.